Functional Glycogenomics

Research summary:

The laboratory's main purpose is to understand as the innate immune system recognizes pathogens through surface receptors - basically CLRs or C-type lectins and galectins-expressed mainly in macrophages and dendritic cells. In the past year we have developed a system of study that includes the full complement of glycan recognition proteins (human and murine) immobilized microarray format that will allow us to get a snapshot of how a particular pathogen is "seen" by the immune system. The results of studies using this predictive system may provide clues as to bias the immune response generated against a particular pathogen. A second objective is to define routes signaling / transduction induced in antigen presenting cells by the interaction of C-type lectins and galectinshaptens with their glycans. Knowing the nature of these pathways is essential for the identification of pathogen molecules that may act as regulators / immune modulators and hence serve as potential therapeutic targets for development of novel treatments. Thirdly, is proposed to define the mechanisms by which the hoist c-type lectins are able to induce cellular activation programs leading to a decreased response to pro-inflammatory TLR ligands. In particular, consideration taken to decipher which combination of type C lectins / galectins-TLR is required for a specific immune response. Could ligands / glycans derived from pathogens, could be used as adjuvants Th1 or Th2? An approach that would answer this question, is to address the interaction of antigens previously demonstrated with some protective activity of Leishmania sp. towards skin dendritic cells through their fusion to CLRs ligands in order to stimulate a specific immune response.


T cruzi amastigotes take over soluble intracellular pool of galectins.
LLC-MK2 cells growing onto glass coverslips were infected. After four days p.i., the cells were processed for immunofluorescence and stained with anti galectin 1 (A and B), galectin 3 (C and D).


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Bonay MiaronsPedro4084509pbonay(at)cbm.csic.esProfesor Titular Universidad, GA
Martín-Portugues RodriguezSergio4084509Estudiante TFG
Noguera OishiLaura Ayaka4509Estudiante TFG
Serrano PérezIrene4084509Estudiante

Relevant publications:

  • Aquilino, C., Gonzalez Rubio, M.L., Seco, E.M., Escudero, L., Corvo, L., Soto, M., Fresno, M., Malpartida, F., and Bonay, P. (2012) Differenti altrypanocidal activity of novel macrolide antibiotics; correlation to genetic lineage. PLoS One 7(7):e40901.
  • de la Fuente, H., Pérez-Gala, S., Bonay, P., Cruz-Adalia, A., Cibrian, D., Sánchez-Cuellar, S., Dauden, E., Fresno, M., García-Diez, A., and Sánchez-Madrid, F. (2012). Psoriasis in humans is associated with down-regulation of galectins in dendritic cells. J Pathol228(2):193-203.
  • Carneiro, M.X., Santos, D.M., Fukutani, K.F., Clarencio, J., Miranda, J.C., Brodskyn, C., Barral, A., Barral-Netto, M., Soto, M. and de Oliveira, C.I. (2012) Vaccination with L. Infantumchagasi nucleosomal histones confers protection against New World Cutaneous Leishmaniasis caused by Leishmania braziliensis. PLoS One 7(12), e52296.
  • Valadares, D.G., Duarte, M.C., Ramírez, L., Chávez-Fumagalli, M.A., Martins, V.T., Costa, L.E., Lage, P.S., Ribeiro, T-G., Castilho, R.O., Fernandes, A.P., Régis, W.C., Soto, M., Tavares, C.A. and Coelho, E.A. (2012) Prophylactic or therapeutic administration of Agaricusblazei murillis effective in treatment of murine visceral leishmaniasis. Exp. Parasitol., 132, 228-236.
  • Valadares, D.G., Duarte, M.C.m Ramírez, L., Chávez-Fumagalli, M.A., Lage, P.S., Martins, V.T., Costa, L.E., Ribeiro, T.G., Régis, W.C., Soto, M., Fernandes, A.P., Tavares, C.A. and Coelho, E.A. (2012) Therapeutic efficacy induced by the oral administration of Agaricusblazei Murill against Leishmania amazonensisParasitol. Res. 111, 1807-1816.


  • Carlos Alonso, Manuel Soto, Laura Ramírez, Jerónimo Carnés, Marta Román. Molecule for treating an inflammatory disorder. Publication number: WO 2012/152792 A1 (15/11/2012).Laboratorios CBF LETI S.L. Unipersonal.
  • Carlos Alonso, Laura Ramírez, Manuel Soto. The use of an L3 and/or L5 source as a vaccine or as a diagnostic for a parasitic disease. Publication number: WO 2011/058137 A1 (15/05/2011). Laboratorios CBF LETI S.L. Unipersonal.
  • Manuel Soto, Laura Ramírez and Carlos Alonso. "Diagnosis of a parasitic disease such as leishmaniasis using ribosomal protein extracts (RPE)". Publication number: WO 2011/006891 A1( 20/01/2011). Laboratorios CBF LETI S.L. Unipersonal.

Other activities:

  • Pedro Bonay Miarons ha sido nombrado representante español en “International Glycoconjugate Organization”.

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand


What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: